CD44v10: An Antimetastatic Membrane Glycoprotein for Pancreatic Cancer

Aims The aims of this study were 1) to investigate the mRNA pattern of CD44 variants in three primary (MIA PaCa 2, PANC-1, PSN-1) and two metastatic (CAPAN-1, SUIT-2) pancreatic cancer (PC) cell lines; 2) to ascertain whether the genetic transfer of CD44s and CD44v10 modifies the adhesion of PC cells to the extracellular matrix (ECM) in vitro and their metastatic behavior in vivo. Methods CD44 mRNA analysis was done by means of RT-PCR. Adhesion to ECM the was assessed using coated microtiter plates. For the study of CD44v10 insertion in the CAPAN-1 line, liposome-mediated DNA transfer was used. SCID mice were employed for in vivo experiments. Results CD44v10 mRNA was not expressed by the CAPAN-1 nor by four of the six SUIT-2-derived clones. The stable expression of CD44v10 by modified CAPAN-1 significantly enhanced fibronectin adhesion. Mice without either liver or pancreatic metastases were more frequently found among the animals injected with modified (CD44v10 expressing) than with non-modified CAPAN-1. Conclusions 1) It is possible to differentiate between metastatic and non-metastatic PC cells on the basis of CD44v10 expression; 2) CD44v10 seems to be involved in mediating fibronectin adhesion in vitro and in counteracting metastases in vivo.

[1]  S. Wagner,et al.  Hyaluronan-independent adhesion of CD44H+ and CD44v10+ lymphocytes to dermal microvascular endothelial cells and keratinocytes. , 2001, The Journal of investigative dermatology.

[2]  M. Kaneko,et al.  CD44s expression mitigates the phenotype of human colorectal cancer hepatic metastases. , 2001, Anticancer research.

[3]  A. Cooperman.  Pancreatic cancer: the bigger picture. , 2001, The Surgical clinics of North America.

[4]  K. Vanderkerken,et al.  A unique pathway in the homing of murine multiple myeloma cells: CD44v10 mediates binding to bone marrow endothelium. , 2001, Cancer research.

[5]  S. Watt,et al.  Adhesion receptors on haematopoietic progenitor cells , 2001, British journal of haematology.

[6]  B. Eriksson,et al.  Expression of CD44 variant isoforms and association to the benign form of endocrine pancreatic tumours. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  S. Kagawa,et al.  Analysis of CD44 isoform v10 expression and its prognostic value in renal cell carcinoma , 2000, BJU international.

[8]  M. Plebani,et al.  Cytokines modulate MIA PaCa 2 and CAPAN-1 adhesion to extracellular matrix proteins. , 1999, Pancreas.

[9]  S. Goodison,et al.  CD44 cell adhesion molecules. , 1999, Molecular pathology : MP.

[10]  J. Lévesque,et al.  CD44 isoforms in normal and leukemic hematopoiesis. , 1999, Experimental hematology.

[11]  M. Zöller,et al.  Involvement of CD44 variant isoform v10 in progenitor cell adhesion and maturation. , 1999, Experimental hematology.

[12]  G. Adler,et al.  Integrin α6β1 role in metastatic behavior of human pancreatic carcinoma cells , 1999 .

[13]  H. Miyake,et al.  Highly specific and sensitive detection of malignancy in urine samples from patients with urothelial cancer by CD44v8–10/CD44v10 competitive RT‐PCR , 1998, International journal of cancer.

[14]  Y. Kanai,et al.  Expression of CD44 Variants and Its Association with Survival in Pancreatic Cancer , 1998, Japanese journal of cancer research : Gann.

[15]  M. Zeitz,et al.  Decreased expression of CD44 splicing variants in advanced colorectal carcinomas. , 1998, European journal of cancer.

[16]  D. Mangham,et al.  The normal structure and function of CD44 and its role in neoplasia. , 1998, Molecular pathology : MP.

[17]  Borland,et al.  Forms and functions of CD44 , 1998, Immunology.

[18]  I. Saiki.  Cell adhesion molecules and cancer metastasis. , 1997, Japanese journal of pharmacology.

[19]  M. Hollingsworth,et al.  P-selectin expression in a metastatic pancreatic tumor cell line (SUIT-2). , 1997, Cancer research.

[20]  S. Rosewicz,et al.  Retinoids inhibit adhesion to laminin in human pancreatic carcinoma cells via the alpha 6 beta 1-integrin receptor. , 1997, Gastroenterology.

[21]  Masahiro Yamamoto,et al.  The Significance of CD44 in Human Pancreatic Cancer: II. The Role of CD44 in Human Pancreatic Adenocarcinoma Invasion , 1994, Pancreas.

[22]  W. Jiang,et al.  Molecular and cellular basis of cancer invasion and metastasis: Implications for treatment , 1994, The British journal of surgery.

[23]  J. Bell,et al.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[24]  L. Liotta,et al.  Tumor invasion and metastasis: an imbalance of positive and negative regulation. , 1991, Cancer research.

[25]  Y Iwamoto,et al.  A rapid in vitro assay for quantitating the invasive potential of tumor cells. , 1987, Cancer research.

[26]  S. Batra,et al.  CD44 in normal human pancreas and pancreatic carcinoma cell lines. , 2001, Teratogenesis, carcinogenesis, and mutagenesis.

[27]  K. Endo,et al.  Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. , 2000, Journal of hepatology.

[28]  T. Ishida.  Immunohistochemical Expression of the CD44 Variant 6 in Colorectal Adenocarcinoma , 2000, Surgery Today.

[29]  R. Silverstein,et al.  Cell adhesion molecules: an overview. , 1998, Cancer investigation.

[30]  Ronit Vogt Sionov,et al.  CD44: structure, function, and association with the malignant process. , 1997, Advances in cancer research.

[31]  H. Orzechowski,et al.  Increased fibronectin-receptor expression in colon carcinoma-derived HT 29 cells decreases tumorigenicity in nude mice. , 1994, Gastroenterology.